WO2022159581A3 - Artemisinin-proteasome inhibitor conjugates and their use in the treatment of disease - Google Patents

Artemisinin-proteasome inhibitor conjugates and their use in the treatment of disease Download PDF

Info

Publication number
WO2022159581A3
WO2022159581A3 PCT/US2022/013129 US2022013129W WO2022159581A3 WO 2022159581 A3 WO2022159581 A3 WO 2022159581A3 US 2022013129 W US2022013129 W US 2022013129W WO 2022159581 A3 WO2022159581 A3 WO 2022159581A3
Authority
WO
WIPO (PCT)
Prior art keywords
artemisinin
treatment
proteasome inhibitor
disease
disorders
Prior art date
Application number
PCT/US2022/013129
Other languages
French (fr)
Other versions
WO2022159581A9 (en
WO2022159581A2 (en
Inventor
Gang Lin
Wenhu ZHAN
Hao Zhang
Laura KIRKMAN
Carl Nathan
Daqiang Li
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Priority to EP22743162.4A priority Critical patent/EP4281066A2/en
Publication of WO2022159581A2 publication Critical patent/WO2022159581A2/en
Publication of WO2022159581A3 publication Critical patent/WO2022159581A3/en
Publication of WO2022159581A9 publication Critical patent/WO2022159581A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The Artemisinin-Proteasome inhibitor conjugate compounds of the present application are represented by the following compounds having Formula (I) where the substituents R1-R5, X, Y, Y', and Z are defined herein. These compounds are used in the treatment of cancer, immunologic disorders, autoimmune disorders, neurodegenerative disorders, or inflammatory disorders, infectious disease, or for providing immunosuppression for transplanted organs or tissues.
PCT/US2022/013129 2021-01-20 2022-01-20 Artemisinin-proteasome inhibitor conjugates and their use in the treatment of disease WO2022159581A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP22743162.4A EP4281066A2 (en) 2021-01-20 2022-01-20 Artemisinin-proteasome inhibitor conjugates and their use in the treatment of disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163139638P 2021-01-20 2021-01-20
US63/139,638 2021-01-20

Publications (3)

Publication Number Publication Date
WO2022159581A2 WO2022159581A2 (en) 2022-07-28
WO2022159581A3 true WO2022159581A3 (en) 2022-09-09
WO2022159581A9 WO2022159581A9 (en) 2022-10-27

Family

ID=82549065

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/013129 WO2022159581A2 (en) 2021-01-20 2022-01-20 Artemisinin-proteasome inhibitor conjugates and their use in the treatment of disease

Country Status (2)

Country Link
EP (1) EP4281066A2 (en)
WO (1) WO2022159581A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100093651A1 (en) * 2006-10-20 2010-04-15 Brando Lorraine V Artemisinin Derivatives
WO2014100486A1 (en) * 2012-12-21 2014-06-26 University Of Washington Through Its Center For Commercialization Artemisinin compounds and synthesis and use thereof
WO2015155303A2 (en) * 2014-04-11 2015-10-15 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Medical use of artemisinin compounds and gephyrin agonists
US20160228457A1 (en) * 2013-04-09 2016-08-11 Stc.Unm Method for cancer cell reprogramming

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100093651A1 (en) * 2006-10-20 2010-04-15 Brando Lorraine V Artemisinin Derivatives
WO2014100486A1 (en) * 2012-12-21 2014-06-26 University Of Washington Through Its Center For Commercialization Artemisinin compounds and synthesis and use thereof
US20160228457A1 (en) * 2013-04-09 2016-08-11 Stc.Unm Method for cancer cell reprogramming
WO2015155303A2 (en) * 2014-04-11 2015-10-15 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Medical use of artemisinin compounds and gephyrin agonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KIRKMAN, LA ET AL.: "Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 115, no. 29, 17 July 2018 (2018-07-17), pages E6863 - E6870, XP055593481, DOI: 1 10.1073/pnas.1806109115 *
ZHAN WENHU, LIU YI JING, YANG CHANGMEI, ZHANG HAO, HARRIS JACOB C., WANG RONG, ZHU SONGBIAO, SHERMAN JULIAN, SUKENICK GEORGE, RODR: "Artemisinin-based hybrids produce intracellular proteasome inhibitors that overcome resistance in Plasmodium falciparum", BIORXIV, 21 June 2021 (2021-06-21), XP055967748, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2021.06.21.449268v1.full.pdf> [retrieved on 20221004], DOI: 10.1101/2021.06.21.449268 *

Also Published As

Publication number Publication date
EP4281066A2 (en) 2023-11-29
WO2022159581A9 (en) 2022-10-27
WO2022159581A2 (en) 2022-07-28

Similar Documents

Publication Publication Date Title
EA200500174A1 (en) NEW BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS
EG25613A (en) Thienopyrimidinediones and their use in the modulation of autoimmune disease
WO2020257549A3 (en) Compounds for treatment of pd-l1 diseases
ID23666A (en) COMPOUND CHEMICALS
UA86970C2 (en) Morpholine compounds
BRPI0415185A (en) 2h- [1,2,4] triazole [4,3-a] substituted pyrazines as gsk-3 inhibitors
CA2370888A1 (en) Renin inhibitors
EA200700902A1 (en) 3-ARYLAMINOPYRIDINE DERIVATIVES
ATE538124T1 (en) IMIDAZOCONDENSED TRICYCLIC COMPOUNDS BASED ON THIAZOLOA4,5-BUPYRIDINE AND PHARMACEUTICAL COMPOSITIONS THEREOF
AU2002321910A1 (en) Pyrazole-derived kinase inhibitors and uses thereof
EP2251327A3 (en) Heterocyclic inhibitors of MEK and methods of use thereof
CA2260777A1 (en) Pentafluorobenzenesulfonamides and analogs
TW200630374A (en) Thiazolyldihydroindazoles
HK1089163A1 (en) Quinoxaline derivatives as neutrophil elastase inhibitors and their use
CY1117094T1 (en) 2-PHENYLHYTHLAMINE PRODUCER AS MODIFICATIONS OF CALCIUM AND / OR Sodium
TW200604196A (en) New quinuclidine derivatives and pharmaceutical compositions comprising them
DK1641454T3 (en) Pyrazolo [3,4-B] pyridin-6-ones as GSK-3 inhibitors
MX2023002269A (en) Inhibitors of apol1 and methods of using same.
CR20210513A (en) Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease
ATE462705T1 (en) A1,2,4ÜTRIAZOLOÄ1,5-AÜPYRIMIDINE-2-YLUREA DERIVATIVE AND USE THEREOF
CR20220478A (en) Benzodiazepine derivatives as gaba a gamma1 pams
UA92009C2 (en) 4-PHENYL-5-0X0-l,4,5,6,7,8-HEXAHYDR0QЛIN0LINE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OF INFERTILITY
WO2022159581A3 (en) Artemisinin-proteasome inhibitor conjugates and their use in the treatment of disease
SE0203070D0 (en) Novel compounds
CA3200722A1 (en) Heteroaryl-acetylenes, pharmaceutical compositions thereof, and their therapeutic applications

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22743162

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022743162

Country of ref document: EP

Effective date: 20230821

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22743162

Country of ref document: EP

Kind code of ref document: A2